Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025, emphasizing continued progress across its key clinical programs. The company highlighted advancements in its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, along with a completed leadership transition and corporate rebranding.
The company ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026. The company's proprietary novel serotonergic agonists (NSAs) are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs. For more details, the full press release is available at https://ibn.fm/VigPf.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma is the commercial operating name of Cybin Inc., founded in 2019.
These results are significant as they demonstrate Helus Pharma's continued advancement of its clinical pipeline, particularly the Phase 3 program for major depressive disorder, which if successful, could provide a new treatment option for patients with unmet needs. The company's strong cash position provides a runway to achieve key milestones, including data readouts anticipated in 2026.
